Inflammaging in Clinical Practice: GlycanAge’s New Data

Why It Matters

Accurate measurement of chronic inflammation enables early, individualized interventions, turning preventive health into a data‑driven practice. This could reshape how clinicians address aging‑related risk before disease manifests.

Key Takeaways

• Glycan profiles reflect long‑term immune inflammation.
• GlycanAge offers personalized, early‑stage health monitoring.
• Event targets clinicians to adopt inflammaging diagnostics.
• Glycans fill missing layer in immunology research.
• Partnerships with Mayo, Harvard accelerate clinical validation.

Pulse Analysis

Glycans—complex sugar chains attached to proteins—have long been a blind spot in immunology, despite their central role in regulating protein function and immune signaling. Recent advances reveal that glycan patterns shift predictably with age, lifestyle and environmental stressors, providing a molecular fingerprint of "inflammaging," the subtle, chronic inflammation that underlies many age‑related diseases. By moving beyond genetic and proteomic snapshots, glycan research offers a dynamic, systems‑level view of the aging immune system, opening new avenues for both basic science and clinical insight.

GlycanAge leverages this science to create a blood‑based glycan‑profile test that captures long‑term inflammatory status, unlike acute markers such as C‑reactive protein that fluctuate daily. The platform quantifies a "threshold moment"—the point where biological drift precedes overt symptoms—allowing patients and physicians to evaluate the real‑world impact of diet, supplements, hormone therapy or stress‑reduction strategies within months. The upcoming Dubrovnik symposium, co‑hosted with ISABS and Mayo Clinic, is designed to equip clinicians with practical workflows for integrating these measurements into routine care, turning abstract aging concepts into actionable data.

If validated at scale, glycan‑based diagnostics could catalyze a broader shift in the longevity market from speculative products to evidence‑based interventions. Regulatory pathways are emerging for biomarkers that predict cardiovascular events or diabetes risk, and GlycanAge’s collaborations with leading hospitals position it to meet those standards. For investors and health systems, the promise is twofold: a new revenue stream from precision‑preventive testing and the potential to reduce costly chronic disease treatment by intervening earlier, guided by personalized glycan signatures. This convergence of science, clinical demand, and cultural focus on immune resilience marks a pivotal moment for aging medicine.